Pulmonary hypertension in interstitial lung disease

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 5, 2008, Pages 462-469

  Polomis, David ^a   Runo, James R ^a   Meyer, Keith C ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bosentan; Epoprostenol; Idiopathic pulmonary fibrosis; Iloprost; Interstitial lung disease; Pulmonary arterial hypertension; Sarcoidosis; Scleroderma; Sildenafil; Treprostinol

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; BOSENTAN; CYCLOPHOSPHAMIDE; ETANERCEPT; GAMMA1B INTERFERON; ILOPROST; PIRFENIDONE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST; ANTIHYPERTENSIVE AGENT;

ANEMIA; CLINICAL TRIAL; COLLAGEN DISEASE; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; COUGHING; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEART CATHETERIZATION; HEMODYNAMICS; HEPATITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPOTENSION; INCIDENCE; INJECTION SITE PAIN; INTERSTITIAL LUNG DISEASE; LUNG EDEMA; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MONOTHERAPY; MORBIDITY; MORTALITY; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SARCOIDOSIS; SCLERODERMA; STRESS ECHOCARDIOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR DISEASE;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION;

EID: 53149117497     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283043e30     Document Type: Review

References (55)

1. Rubin LJ. Pulmonary arterial hypertension. Proc AmThorac Soc 2006; 3:111-115.
2. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131:1917-1928.
3. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:14S.
4. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167:735-740.
5. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129:746-752.
6. Nadrous HF, Pelikka PA, Krowka MJ, et al. Pulmonary hypertension complicating idiopathic pulmonary fibrosis. Chest 2005; 128:2393-2399.
7. Nathan SD, Ahmad S, Koch J, et al. Serial measures of pulmonary artery pressures in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 168S.
8. Shorr AF, Wainright JL, CorsCS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30:715-721.
9. Wigley FM, LimaJA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease atthe secondary healthcare level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52:2125-2132.
10. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Int Med J 2007; 37:485-494.
11. Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med 2007; 13:484-488.
12. Shorr AF, Helman DL, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122:233-238.
13. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161:216-223.
14. Taveira-DaSilva AM, Hathaway OM, Sachdev V, et al. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007; 132:1573-1578.
15. Whelan TP, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24:1269-1274.
16. Lederer DJ, Caplan-Shaw CE, O'Shea MK, et al. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 2006; 6:398-403.
17. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25:783-788.
18. Girgis RE, Mathai SC, Krishnan JA, et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005; 24:1626-1631.
19. Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11:452-455.
20. Giaid A, Michel RP, Steward DJ, et al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341:1500-1554.
21. Trakada G, Spiropoulos K. Arterial endothelin-1 in interstitial lung disease patients with pulmonary hypertension. Monaldi Arch Chest Dis 2001; 56: 379-383.
22. Patel NM, Lederer DL, Borczak AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132:998-1006.
23. Charbeneau RP, Peters-Golden M. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 2005; 108:479-491.
24. ColombatM, MalH,Groussard O, et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic studies on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007; 38: 60-65.
25. van Laar JM, Stolk J, Tyndall A. Scleroderma lung: pathogenesis, evaluation, and current therapy. Drugs 2007; 67:985-996.
26. Kowal-Bielecka O, Kowal K, Distler O, et al. Cyclooxygenase and lipoxygen-ase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 2005; 52:3783-3791.
27. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68-74.
28. Ryu JH, McGoon MD. Pulmonary hypertension associated with interstitial lung disease. UpToDate 2007 version 15.3;1-13.
29. Provencher S, JaisX, Yaici A, et al. Clinical challenges in pulmonary hypertension. Chest 2005; 128:622S-628S.
30. Bossone E, Bodini BD, MazzaA, AllegraL. Pulmonary artery hypertension: the key role of echocardiography. Chest 2005; 127:1836-1843.
31. Zisman DA, Karlamangla AS, Ross DJ, et al. High-resolution chestCTfindings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007; 132:773-779.
32. Luechte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170:360-365.
33. Meyer KC. Idiopathic pulmonary fibrosis, part 2: the current approach to treatment. J Respir Dis 2007; 28:331-338.
34. KingTEJr, BehrJ, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75-81.
35. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon γ1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 123-133.
36. Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest 2007; 132:637-649.
37. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666.
38. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54:3962-3970.
39. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153:1037-1047.
40. O'Callaghan D, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007; 28:169-185.
41. Benza RL, Park MH, Keogh A, Girgis RE. Management of pulmonary arterial hypertension with a focus on combination therapy. J Heart Lung Transplant 2007; 26:437-446.
42. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24:353-359.
43. McLaughlin VV, Oudiz R, Frost A, et al. A randomized, double-blind, placebo-controlled study of iloprost inhalation as add-on therapy to bosentan in pulmonary arterial hypertension. Chest 2005; 128:160S.
44. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary artery hypertension. Eur Respir J 2005; 26:858-863.
45. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002; 360:895-900.
46. Olchewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit care Med 1999; 160:600-607.
47. Inhaled iloprost in adults with abnormal pulmonary pressure and associated with idiopathic pulmonary fibrosis. ClinicalTrials.gov #NCT00109681 available at http://clinicaltrials.gov. [Accessed 10 February 2008].
48. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131:897-899.
49. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 27:329-334.
50. Ahmadi-Simab K, Hellmich B, Gross WL. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Eur J Clin Invest 2006; 36 (Supp 3):44-48.
51. Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130:1481-1488.
52. Meyer KC, Cardoni A, Xiang Z. Vascular endothelial growth factor in bronch-oalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J Lab Clin Med 2000; 135:332-338.
53. Alalawi RA, Whelan TB, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med 2005; 11:461-466.
54. Fitton TP, Kosowski TR, Barreiro CJ, et al. Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005; 24: 1254-1259.
55. Schachna L,Medsger TAJr, Dauber JH, et al. Lung transplantationincompared with idiopathic pulmonary fibrosis and idiopathic pulmonary artery hypertension. Arthritis Rheum 2006; 54:3954-3961.